Zydus Gets USFDA Clearance for Ankleshwar API Plant After Clean Inspection

has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Ankleshwar, Gujarat. The inspection took place from March 10 to March 14, 2025, and has been classified as "No Action Indicated" (NAI), which means the USFDA did not find any issues or irregularities. This confirms that the inspection is now officially closed by the regulator. The NAI status is a positive sign of compliance and quality, helping Zydus maintain trust in its global pharmaceutical operations. Follow me for more such posts, Thank You! Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.